incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
== History == Both Adolf Jarisch, an Austrian dermatologist, and Karl Herxheimer, a German dermatologist, are credited with the discovery of the Jarisch–Herxheimer reaction. Both Jarisch and Herxheimer observed reactions in patients with syphilis treated with mercury. The reaction was first seen following treatment in early and later stages of syphilis treated with Salvarsan, mercury, or antibiotics. Jarisch thought that the reaction was caused by a toxin released from the dying spirochetes.
August 23: Decree enacting the International Convention for the Suppression of the White Slave Traffic (signed on May 4, 1910). November 16: Law amending Article 340 of the Civil Code (Judicial recognition of natural paternity). December 23: The administrative boards of public low-income housing offices (Habitations à Bon Marché, HBM) are opened to women. June 17, 1913: Law on postpartum rest for women. August 5, 1914: Law granting allowances to needy families during the war if the breadwinner is conscripted or recalled to military service (France declared general mobilization on August 2 and entered World War I that same month). 1916
==== National Strategy for Connected Schools ==== In September 2023, the government launched the National Strategy for Connected Schools (ENEC). The program is structured around four main connectivity pillars: deployment of high-speed internet access infrastructure; provision of adequate internet connectivity; installation of Wi-Fi networks in schools; and supply of electrical power. ENEC will receive investments of 8.8 billion reais, of which 6.5 billion reais come from the “Digital Inclusion and Connectivity” axis of the New PAC. Funding comes from four sources: the 5G auction, the Universal Service Fund for Telecommunications (Fust), the Connected Education Innovation Program (PIEC) and Law No. 14,172 of 2021.
Sources: en.wikipedia.org
== Location and characteristics == The location of prolactin cells within the pituitary gland is regulated largely by the hypothalamus. The pituitary gland is divided into posterior and anterior regions. Within the anterior pituitary gland are the prolactin cells, where they secrete the hormone prolactin. Prolactin cells vary in number, size, and appearance depending on female reproductive status. Prolactin cells specifically increase in response to the physiological state of pregnancy, in particular, the need for the development of breast tissues and milk production. During pregnancy, prolactin cells will undergo hypertrophy (enlarging to support increased prolactin production) as well as hyperplasia (an increase in cell number). The pituitary gland increases in size due to the amount of prolactin cells. The secretory granules of prolactin cells fluctuate from sparsely granulated (during periods of low prolactin production) to densely granulated (during periods of high prolactin production). Prolactin cells contain a large amount of rough endoplasmic reticulum, where prolactin synthesis occurs. The trans-Golgi layer is responsible for storing the prolactin hormone into secretory granules, which are dissolved upon secretion out of the cell. Lysosomal enzymes are involved in the degradation of the secretory granules. The prolactin hormone is a single polypeptide chain protein composed of 199 amino acids in humans. It consists of “three intramolecular disulfide bonds located between six cysteine residues (Cys4-Cys11, Cys58-Cys174, and Cys191-Cys199”.
== Release == The film premiered at the 62nd Cannes Film Festival on 18 May 2009, and went on to screen at festivals such as the Toronto International Film Festival and the Maryland Film Festival. It was released in Greece on 11 November 2009 by Feelgood Entertainment. Verve Pictures acquired distribution rights for the United Kingdom and released it on 23 April 2010. Kino International released it in the United States on 25 June 2010.
== Further reading == Holmer, Marianne. Aquaculture in the Ecosystem. Dordrecht, Netherlands: Springer, 2008. Molyneaux, Paul. Swimming in Circles: Aquaculture and the End of Wild Oceans. New York: Thunder's Mouth Press, 2006. Stickney, Robert R. Aquaculture: An Introductory Text. Oxford, UK; Cambridge, MA: CABI Publishing, 2005. World Bank. Changing the Face of the Waters: The Promise and Challenge of Sustainable Aquaculture. Washington, DC: World Bank, 2007.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。